Pharmacology · Cardiovascular

Hypertension in Pregnancy

Classification, safe agents, acute management, and magnesium sulfate monitoring

Four distinct hypertensive disorders of pregnancy carry different risk profiles: chronic hypertension predates 20 weeks and carries a 20 to 25 percent risk of superimposed preeclampsia; gestational hypertension appears after 20 weeks without severe features and resolves postpartum but carries a 15 to 25 percent risk of progression; preeclampsia is defined by blood pressure at or above 140/90 after 20 weeks plus at least one severe feature, caused by abnormal placentation driving systemic endothelial dysfunction through anti-angiogenic factors; HELLP syndrome and eclampsia are life-threatening preeclampsia variants requiring immediate delivery.
Three oral agents form the pregnancy-safe antihypertensive armamentarium: labetalol (combined alpha-beta blockade, no reflex tachycardia, dual oral and IV utility), long-acting nifedipine (extended-release only — sublingual immediate-release is contraindicated due to precipitous hypotension), and methyldopa (the longest safety record with 7-year child development follow-up data, but sedation limits its use outside pregnancy).
ACE inhibitors and ARBs are absolutely contraindicated in all trimesters: fetal kidneys depend on angiotensin II for normal development, and blockade causes renal dysgenesis, severe oligohydramnios, pulmonary hypoplasia, limb contractures, and neonatal renal failure — discontinue immediately on confirmed pregnancy.
Acute severe hypertension (systolic at or above 160 or diastolic at or above 110) must be treated within 30 to 60 minutes: labetalol IV and oral nifedipine are first-line; hydralazine IV is third-line due to less predictable response and more reflex tachycardia; the sublingual route for nifedipine remains contraindicated even in the acute setting.
Magnesium sulfate prevents and treats eclamptic seizures but is not an antihypertensive — antihypertensive drugs must continue in parallel; the therapeutic window is 4 to 7 mEq/L, loss of deep tendon reflexes signals early toxicity at 7 to 10 mEq/L, respiratory depression follows at 10 to 13 mEq/L, and the antidote is calcium gluconate 1 g IV over 3 minutes.

Abbreviations: HTN = hypertension · BP = blood pressure · SBP = systolic blood pressure · DBP = diastolic blood pressure · ACEi = angiotensin converting enzyme inhibitor · ARB = angiotensin receptor blocker · RAAS = renin-angiotensin-aldosterone system · IV = intravenous · HR = heart rate · sFlt-1 = soluble fms-like tyrosine kinase 1 · LDH = lactate dehydrogenase · AST = aspartate aminotransferase · ALT = alanine aminotransferase · ULN = upper limit of normal · DTR = deep tendon reflex · mEq/L = milliequivalents per liter · HELLP = hemolysis, elevated liver enzymes, low platelets · MRA = mineralocorticoid receptor antagonist · FDA = Food and Drug Administration

Classification of Hypertensive Disorders of Pregnancy

Four Categories — Each with Distinct Risk Profile and Management

Quick Reference: Hypertensive Disorders of Pregnancy

Disorder	Onset / Definition	Key Features	Management Highlights
Chronic hypertension	Before 20 weeks or predates pregnancy; BP at or above 140/90	Affects 1–5% of pregnancies; 20–25% risk of superimposed preeclampsia; BP may fall in 2nd trimester masking disease	Switch to pregnancy-safe agents immediately; treat when BP at or above 140/90 (CHAP trial); target SBP 120–159, DBP 80–104
Gestational hypertension	At or after 20 weeks; no proteinuria or severe features	6% of pregnancies; resolves within 12 weeks postpartum; 15–25% risk of progressing to preeclampsia; ~50% develop chronic HTN within 10 years	Treat severe-range BP; monitor closely for preeclampsia features
Preeclampsia	At or after 20 weeks; BP at or above 140/90 plus at least one severe feature (proteinuria no longer required)	Caused by abnormal placentation → placental ischemia → anti-angiogenic factors (sFlt-1) → systemic endothelial dysfunction; severe features: SBP at or above 160 or DBP at or above 110, thrombocytopenia, creatinine above 1.1, transaminases above 2x ULN, pulmonary edema, headache unresponsive to acetaminophen	Antihypertensives for BP control; magnesium sulfate for seizure prophylaxis in severe disease; delivery is definitive treatment
HELLP syndrome	Severe preeclampsia variant; BP may be only mildly elevated or normal in 15–20% of cases	Hemolysis (elevated LDH, schistocytes); Elevated Liver enzymes (AST/ALT above 2x ULN); Low Platelets (below 100,000; severe below 50,000)	Delivery; corticosteroids for fetal lung maturity if below 34 weeks; magnesium sulfate; antihypertensives
Eclampsia	Grand mal seizure in patient with preeclampsia; antepartum, intrapartum, or postpartum (up to 4 weeks)	Magnesium sulfate: treatment AND prophylaxis; is NOT an antihypertensive — antihypertensive therapy must continue in parallel	Magnesium sulfate loading 4–6 g IV; antihypertensives for BP; delivery is definitive

Antihypertensive Agents in Pregnancy — Safe vs Contraindicated

First-Line Oral Agents (CHAP-Supported)

Safe Antihypertensives in Pregnancy

Labetalol (oral): 100–400 mg two to three times daily; combined alpha/beta blockade — no reflex tachycardia; dual oral and IV utility; monitor neonate for bradycardia and hypoglycemia; avoid in asthma
Nifedipine long-acting (oral only): 30–90 mg once daily; extended-release only — sublingual immediate-release is contraindicated (precipitous BP drop); enhanced hypotension with concurrent magnesium sulfate
Methyldopa (oral): 250–500 mg two to three times daily; longest safety record in pregnancy — 7-year child development follow-up data; most common adverse effect is sedation; positive Coombs test in up to 20%
Hydralazine (oral or IV): oral second-line; IV used for acute severe hypertension; less predictable onset than labetalol or nifedipine; third-line for acute management
Breastfeeding: labetalol, nifedipine, methyldopa, captopril, and enalapril (full-term neonates only) are compatible; ARBs and spironolactone generally avoided

Absolutely Contraindicated — All Trimesters

Agents That Harm the Fetus

ACE inhibitors and ARBs — ABSOLUTE CONTRAINDICATION: fetal kidneys depend on angiotensin II for normal development; blockade causes fetal renal dysgenesis, severe oligohydramnios (can cause fetal demise), pulmonary hypoplasia, limb contractures, neonatal renal failure, calvarial hypoplasia; FDA black box warning — discontinue immediately on confirmed pregnancy
Direct renin inhibitors (aliskiren): same contraindication as ACEi and ARBs
Sodium nitroprusside: releases cyanide ions; fetal liver has limited cyanide metabolism capacity — avoid unless no other option
Mineralocorticoid receptor antagonists: spironolactone, eplerenone, finerenone — generally avoided; anti-androgenic effects and insufficient human safety data
Sublingual immediate-release nifedipine: not the drug itself but the route — causes precipitous uncontrolled hypotension and fetal distress; use oral swallowed formulation only

Acute Severe Hypertension in Pregnancy — Three Agents

Systolic at or above 160 or Diastolic at or above 110 mm Hg — Treat Within 30–60 Minutes

Parenteral and Acute Oral Protocols

Agent / Route	Dosing Protocol	Key Notes
Labetalol IV (first-line)	20 mg IV over 2 min; then 40 mg after 10 min if inadequate; then 80 mg every 10 min; maximum 300 mg per episode; onset 5–10 min	No reflex tachycardia; titratable; extensive obstetric experience; avoid if asthma, bradycardia, or decompensated heart failure; monitor: do not allow HR below 60 bpm or fetal heart rate changes
Nifedipine oral (first-line)	10 mg immediate-release, swallowed (NOT sublingual); repeat in 20–30 min if still severe; maximum 30 mg per episode; onset 20–30 min	Must be swallowed — sublingual route is contraindicated; enhanced hypotension with concurrent magnesium sulfate; monitor BP closely at 20–30 min intervals
Hydralazine IV (third-line)	5–10 mg IV bolus; repeat every 20–30 min; maximum 20 mg per episode; onset variable (10–30 min)	Less predictable response; reflex tachycardia; more adverse effects (headache, flushing, palpitations); use when labetalol and nifedipine are unavailable or contraindicated

Magnesium Sulfate — Dosing, Therapeutic Window & Toxicity Monitoring

Seizure Prophylaxis Only — NOT an Antihypertensive — Antihypertensives Must Continue in Parallel

Loading 4–6 g IV over 15–20 min → Maintenance 1–2 g/hr → Continue 24–48 hr Postpartum

Therapeutic
4–7 mEq/L

Anticonvulsant effect — goal range

Monitor: deep tendon reflexes (patellar) hourly; respiratory rate (maintain at or above 12/min); urine output (maintain at or above 25 mL/hr — magnesium is renally excreted)

Loss of DTRs
7–10 mEq/L

Earliest clinical sign of toxicity — loss of patellar reflex

Reduce infusion rate; re-check magnesium level; increase monitoring frequency

Respiratory Depression
10–13 mEq/L

Respiratory arrest risk — stop infusion immediately

Stop infusion; give antidote: calcium gluconate 1 g IV (10 mL of 10% solution) over 3 minutes — reverses respiratory depression and cardiac toxicity

Cardiac Arrest
Above 15 mEq/L

Cardiac conduction block and arrest

Stop infusion immediately; calcium gluconate antidote; resuscitation; avoid in severe renal impairment without dose reduction

Antidote — Calcium Gluconate 1 g IV over 3 Minutes

Always have calcium gluconate at the bedside during magnesium sulfate infusion. Calcium directly antagonizes magnesium's effects on neuromuscular transmission and cardiac conduction. Dose: 1 g IV (10 mL of 10% calcium gluconate solution) over 3 minutes. Repeat if needed.

Suggested References

Author / Organization	Title	Source
Katzung BG, ed.	Basic and Clinical Pharmacology. 15th ed.	McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.	McGraw-Hill; 2023
American College of Obstetricians and Gynecologists	Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin No. 222	Obstet Gynecol. 2020;135(6):e237–e260
Magee LA, Maguire PJ, Bhatt M, et al.	ISSHP classification, diagnosis, and management recommendations for international practice	Pregnancy Hypertens. 2022;27:148–169
Tita AT, Szychowski JM, Boggess K, et al.	Treatment for mild chronic hypertension during pregnancy (CHAP trial)	N Engl J Med. 2022;386(19):1781–1792
Cockburn J, Moar VA, Ounsted M, Redman CW	Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children	Lancet. 1982;1(8273):647–649
Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD	Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists	Hypertension. 2012;60(2):444–450
Magee LA, von Dadelszen P, Rey E, et al.	Less-tight versus tight control of hypertension in pregnancy (CHIPS trial)	N Engl J Med. 2015;372(5):407–417
Hale TW, Rowe HE	Medications and Mothers' Milk. 17th ed.	Springer Publishing; 2017
Whelton PK, Carey RM, Aronow WS, et al.	2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults	J Am Coll Cardiol. 2018;71(19):e127–e248
Mol BWJ, Roberts CT, Thangaratinam S, et al.	Pre-eclampsia	Lancet. 2016;387(10022):999–1011
Sibai BM	Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count	Obstet Gynecol. 2004;103(5 Pt 1):981–991
Mancia G, Kreutz R, Brunstrom M, et al.	2023 ESH guidelines for the management of arterial hypertension	J Hypertens. 2023;41(12):1874–2071
Brown MA, Magee LA, Kenny LC, et al.	Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice	Hypertension. 2018;72(1):24–43
Bramham K, Parnell B, Nelson-Piercy C, et al.	Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis	BMJ. 2014;348:g2301